FY2025 EPS Estimates for Pfizer Reduced by Cantor Fitzgerald

Pfizer Inc. (NYSE:PFE - Free Report) - Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of Pfizer in a research note issued on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now anticipates that the biopharmaceutical company will post earnings of $3.09 per share for the year, down from their prior forecast of $3.10. Cantor Fitzgerald has a "Neutral" rating and a $24.00 price target on the stock. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Cantor Fitzgerald also issued estimates for Pfizer's FY2026 earnings at $3.09 EPS.

Several other research firms also recently weighed in on PFE. Berenberg Bank cut their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. HSBC dropped their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Leerink Partners dropped their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Redburn Atlantic decreased their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Finally, Morgan Stanley increased their target price on Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and a consensus price target of $28.55.

Pfizer Price Performance

Shares of PFE stock traded up $0.21 during trading on Thursday, hitting $25.77. The company had a trading volume of 39,477,537 shares, compared to its average volume of 41,842,555. The stock has a market capitalization of $146.49 billion, a price-to-earnings ratio of 18.67, a price-to-earnings-growth ratio of 0.93 and a beta of 0.58. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer has a 52 week low of $20.92 and a 52 week high of $31.54. The stock's 50-day moving average is $23.82 and its two-hundred day moving average is $24.82.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the firm earned $0.82 EPS. The company's revenue was down 7.8% compared to the same quarter last year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.68%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Institutional Trading of Pfizer

Several institutional investors have recently made changes to their positions in the company. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the 4th quarter worth about $27,000. Gould Capital LLC increased its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the 1st quarter worth approximately $27,000. North Capital Inc. purchased a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Finally, Bayforest Capital Ltd acquired a new stake in Pfizer in the 1st quarter valued at approximately $28,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.